News
![Novo Nordisk’s head of development Martin Holst Lange](/sites/default/files/styles/x_large/public/2024-03/martin-holst-lange-novo-nordisk.jpg?itok=UKmSl9ia)
Novo Nordisk agrees $1.1bn takeover of RNA biotech Cardior
Novo Nordisk has reached an agreement to buy Germany’s Cardior Pharmaceuticals for €1.025 billion ($1.1 billion), adding expertise in RNA therapeutics and a heart failure